ALSO READAstrazeneca Pharma India gains after DCGI nod for asthma drug AstraZeneca Pharma India Q4 net loss at Rs 2.87 cr Astrazeneca Pharma India receives Import and Market permission for Asthma drug AstraZeneca Pharma India appoints Gagan Singh Bedi as MD Astrazeneca Pharma India reports standalone net loss of Rs 2.88 crore in the March 2017 quarter
Held on 08 August 2017Astrazeneca Pharma India announced that at the Board meeting of the Company held on 08 August 2017, the Board considered and approved inter alia the following business:
Ian John Parish has been appointed as director (non-executive) on the Board of Directors of the company in the casual vacancy caused by the resignation of Ian Brimicombe, who resigned as director w.e.f 31 May 2017.
2. The Board has approved the convening of the 38th Annual General Meeting of the Company on 13 September 2017.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)